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Venetoclax is a highly selective, potent BCL-2 inhibitor that is approved for some patients previously
treated for chronic lymphocytic leukemia, and has shown promising activity in adult studies across several
hematologic malignancies. Preclinical studies have demonstrated venetoclax activity in pediatric patient-
derived xenograft models and cell lines; however, clinical studies in pediatric patients have yet to be con-
ducted. The prognosis is poor for children with most relapsed/refractory malignancies, and limited treat-
ment options result in unmet clinical need. Herein, we describe the rationale and design of the first study
of venetoclax in pediatric patients with relapsed/refractory malignancies: a Phase I trial investigating the
safety and pharmacokinetics of venetoclax monotherapy followed by the addition of chemotherapy (Trial
registration: EudraCT 2017-000439-14; NCT03236857).
First draft submitted: 9 February 2018; Accepted for publication: 9 March 2018; Published online:
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Members of the BCL-2 protein family are key regulators of the intrinsic apoptotic pathway [1]. The antiapoptotic
proteins of the BCL-2 family prevent activation of proapoptotic proteins that lead to initiation of the mitochondrial
apoptosis pathway, thereby promoting cell survival. Overexpression of BCL-2 family members commonly occurs
in hematologic malignancies and certain solid tumors, resulting in enhanced cancer cell survival [2]. Therefore,
targeting antiapoptotic proteins is a promising therapeutic avenue to explore for pediatric cancer patients.
With new oral targeted therapies becoming more widely available, the landscape of anticancer treatment has
changed considerably. However, drug development in early phase studies of pediatric cancers has been met with
several challenges. These include low single-site patient enrollment numbers due to the relative rarity of many
pediatric cancers, often requiring multicenter and multinational studies to ensure sufficient enrollment, and the
occurrence of disease progression during single-agent studies, particularly for acute leukemias [3]. New study designs
are required that can balance single-agent toxicity, pediatric pharmacokinetics and efficacy with the mechanism
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Figure 1. Mechanism of action of venetoclax.
MOMP: Mitochondrial outer membrane permeabilization.
Adapted from Cancer Discovery, 2016, 6(10), 1106–1117, Konopleva M, Pollyea DA, Potluri J et al. Efficacy and biological correlates of
response in a Phase II study of venetoclax monotherapy in patients with acute myelogenous leukemia, with permission from AACR [6].
of action, and a strong desire of the pediatric research community to incorporate compelling new agents with a
rationally chosen chemotherapy regimen [4,5].
Venetoclax
Venetoclax is a highly selective, potent, orally bioavailable small-molecule inhibitor of the antiapoptotic BCL-2
protein. Venetoclax selectively binds to BCL-2, displacing proapoptotic proteins and leading to mitochondrial
outer membrane permeabilization, activation of caspases and subsequent restoration of apoptosis (Figure 1) [1,6].
Venetoclax is a first-in-class novel BCL-2 inhibitor and the first to be approved in the USA, the EU and other
countries for selected adults with relapsed/refractory chronic lymphocytic leukemia (CLL) [7,8]. Venetoclax is being
evaluated in clinical studies of adult patients with other hematologic malignancies, including multiple myeloma,
acute myeloid leukemia (AML) and non-Hodgkin lymphoma (NHL), both alone and in combination regimens
on the basis of BCL-2 overexpression data in these malignancies [1,9–11].
Data from ongoing adult studies of hematologic malignancies that also occur in children (AML and NHL)
provide a compelling rationale to study venetoclax in children with these malignancies. Promising clinical activity
has been reported for venetoclax monotherapy or combination with other therapies in clinical studies of adult
patients with AML (Table 1) [1,6,9,10,12–29]. Single-agent venetoclax (800 mg daily) demonstrated preliminary
activity in a Phase II study (NCT01994837) of 32 adult patients with relapsed/refractory AML or newly diagnosed
patients unfit for induction chemotherapy. The median age was 71 years (19–84 years) and median time on
venetoclax monotherapy was 63.5 days (range: 14–246 days). The objective response rate (ORR) was 19%, with
complete response (CR) of 6% and CR with incomplete marrow recovery (CRi) of 13% [6].
Data from this study prompted two additional studies of venetoclax in combination with chemotherapy (low-
dose cytarabine) or a hypomethylating agent (azacitidine or decitabine), therapies commonly used to treat AML,
for adult patients with treatment-naive AML. The combination regimens showed preclinical synergistic cytotoxic
activity, and can alter the ratio of BCL-2 family members, leading to an increase in leukemic-cell dependence on
BCL-2 for survival and sensitivity to venetoclax [30]. A Phase I/II study (NCT02287233) evaluating venetoclax
(600 or 800 mg daily) in combination with low-dose cytarabine 20 mg/m2 demonstrated preliminary activity. The
maximum tolerated dose (MTD) was not reached, and daily venetoclax at 600 mg was chosen as the recommended
Phase II dose (RP2D) in this combination, due to dose-limiting toxicities (DLTs) that occurred in two of ten
patients in the 800-mg dose group (grade 4 thrombocytopenia lasting >42 days without evidence of residual
leukemia) [31]. Of 61 patients treated at the RP2D of venetoclax, 64% achieved an ORR, with CR + CRi of 62%
(Table 1) [1,6,9,10,12–29]. Another Phase Ib study (NCT02203773) evaluating venetoclax (400, 800 or 1200 mg)
in combination with a hypomethylating agent (decitabine or azacitidine) also demonstrated significant activity.
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Table 1. Mechanism-based selection of pediatric tumor types.
Pediatric cancer type BCL-2 overexpression Cell line response to venetoclax Murine xenograft response to
venetoclax
Clinical response to venetoclax in
adults
ALL – Upregulation by the MLL–AF4
fusion protein [1,14,15],
TCF3–HLF [16] and hypodiploid
ALL [17]
– Responses in T-ALL, MLL-ALL
and hypodiploid ALL cell lines,
and synergy when combined
with chemotherapy [14,17–19]
– MLL-ALL: 3/6 ORR (1
maintained CR, 1 CR and 1 PR);
B-cell precursor ALL: 3/9 ORR (2
CR and 1 PR) [20]
– Delayed progression in 11/19
xenografts [21]
– Substantial reduction in
leukemia cells in hypodiploid
ALL xenografts [17]
– Not yet tested
AML – High BCL-2 protein levels in
cell lines and patient
samples [9,10]
– 14/24 AML cell lines sensitive
to venetoclax [22]; quick and
potent cell-killing activity [10]
– Synergy when combined with
5-azacitidine [9,23]
– Markedly prolonged overall
survival and significantly
reduced tumor burden [10]
– Venetoclax monotherapy
(800 mg QD): 19% ORR [6]
– Venetoclax (600 mg
QD) + LDAC: 64% ORR [12]
– Venetoclax (400, 800 or
1200 mg QD) + HMA: 67%
ORR [13]
NHL – High BCL-2 expression in cell
lines [1]
– Broad cell-killing activity
demonstrated against a panel
of NHL cell lines [1]
– 100% tumor regression when
combined with bendamustine
and rituximab [1]
– Cell-killing activity in DLBCL
xenografts [24]
DLBCL subtype:
– Venetoclax monotherapy (up to
1200 mg QD): 18% ORR [25]
– Venetoclax (50–1200 mg
QD) + BR: 41% ORR [26]
Neuroblastoma – High BCL-2 expression levels
in certain cell lines [27–29]
– High sensitivity of cell lines to
venetoclax treatment [27]
– Long-term survival in 20% of
mice with monotherapy and
60% in combination with
cyclophosphamide [28]
– Not tested/not applicable
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; BR: Bendamustine/rituximab; CR: Complete response; CRi: Complete response with incomplete marrow recovery;
DLBCL: Diffuse large B-cell lymphoma; HMA: Hypomethylating agent; LDAC: Low-dose cytarabine; MLL: Mixed lineage leukemia; NHL: Non-Hodgkin lymphoma; ORR: Objective response
rate; PR: Partial response; QD: Daily; T-ALL: T-cell acute lymphoblastic leukemia.
Efficacy data from 145 patients aged ≥65 years reported an ORR of 67%, with CR + CRi of 66%. The MTD was
not identified, and the RP2D of venetoclax in this combination was identified as 400 mg, as the best benefit:risk
profile is observed at this dose (Table 1) [1,6,9,10,12–29]. Both combinations (venetoclax + low-dose cytarabine
and venetoclax + azacitidine) are being evaluated in Phase III studies in patients with treatment-naive AML
(NCT03069352, NCT02993523) [32].
Similarly, venetoclax has shown antitumor activity in adult patients with BCL-2-driven relapsed/refractory NHL
in three early phase studies (Table 1) [1,6,9,10,12–29]. A first-in-human dose-escalation Phase I study (NCT01328626)
evaluated venetoclax monotherapy (200–1200 mg daily) in 106 adult patients with relapsed/refractory NHL.
Median age for the overall population was 66 years (25–86 years). The MTD was not reached. 34 patients had
diffuse large B-cell lymphoma (DLBCL), a subtype that occurs in pediatric patients, and among those withDLBCL,
the ORR was 18%, with a CR rate of 12% (Table 1) [1,6,9,10,12–29]. Venetoclax (50–1200 mg daily) in combination
with bendamustine and rituximab (R) was evaluated in an adult Phase I study (NCT01594229). Of 60 patients
enrolled, 22 had DLBCL; the ORR among these patients was 41%, with a CR of 14% (Table 1) [1,6,9,10,12–29].
The MTD was not reached; the RP2D for venetoclax in this combination was 800 mg daily [26], which has
an acceptable benefit:risk ratio in other studies of NHL [33]. An ongoing Phase Ib/II study (NCT02055820) is
evaluating venetoclax with either R or obinutuzumab (G) combined with standard doses of cyclophosphamide,
doxorubicin, vincristine and prednisone (CHOP) in B-cell NHL patients who received one or more prior therapy.
The Phase I portion enrolled a total of 56 patients, 17 with DLBCL. Preliminary data showed 80% of evaluable
DLBCL patients achievedCR, and of the eight BCL-2/Myc double-expressingDLBCL patients, six (75%) achieved
CR. The 200-mg daily dose of venetoclax in cohort 1 was not tolerated. After three patients experienced DLTs in
the first cohort, one patient receiving R-CHOP and two patients receiving G-CHOP (200-mg venetoclax daily
dose), venetoclax was reduced from daily dosing to 10 days of the R-CHOP 21-day cycle. A 10-day dosing regimen
allowed dose escalation to 800 mg venetoclax. The RP2D for venetoclax in combination with R-CHOP is 800 mg
venetoclax 10 days of the 21-day cycle, with acceptable incidence of DLTs [34].
Venetoclax has demonstrated a tolerable safety profile across all studies and indications. The most common
any-grade adverse events (AEs) occurring in ≥20% of patients with CLL (n = 240) were neutropenia, diarrhea,
nausea, anemia, upper respiratory tract infection, thrombocytopenia and fatigue. The most common grade 3 or
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4 AEs occurring in ≥5% of these patients were neutropenia, anemia, thrombocytopenia, febrile neutropenia and
pneumonia. Serious AEs were reported in 43.8% of patients [7].
Initial dose-finding studies in patients with relapsed/refractory CLL resulted in some patients experiencing
clinical tumor lysis syndrome (TLS) [1,35]. To mitigate the risk of TLS, CLL studies thereafter implemented a dose
ramp-up of venetoclax and TLS prophylaxis measures. Data from adult studies suggest that the risk of TLS is low
in other disease settings, though TLS prophylaxis and/or a dose ramp-up tailored to these settings is used. In AML
studies, no clinical TLS has been observed to date, and one patient had laboratory TLS that was managed [6,12,13].
No clinical TLS was observed in NHL studies; however, six patients had laboratory TLS that was managed [25,34].
Pharmacokinetic data available from adult studies have shown peak venetoclax concentrations at 5–8 h following
the first dose. The terminal half-life ranged from 17–41 h following a single dose of venetoclax. In all clinical studies,
venetoclax has been administered with food, as the bioavailability of venetoclax is increased by approximately three-
to five-fold. Venetoclax is predominantly metabolized by the intestinal and hepatic enzyme cytochrome P450
(CYP)3A4. Concomitant use of venetoclax with strong CYP3A inhibitors at initiation and during dose ramp-up is
contraindicated, and use of moderate CYP3A inhibitors, strong or moderate inducers, P-gp inhibitors or narrow
therapeutic index P-gp substrates should be avoided with venetoclax on the basis of clinical drug–drug interaction
studies [7,36–38]. However, if a patient requires use of CYP3A and/or P-gp strong or moderate inhibitors, or in cases
where a concomitant chemotherapeutic is a CYP3A/P-gp inhibitor and will be used after the ramp-up period,
venetoclax dose reduction can be followed according to the prescribing information [7,39].
In addition to clinical data from relevant adult studies, preclinical data were analyzed to identify additional
pediatric tumors with greatest potential to respond to venetoclax. To date, venetoclax has not been evaluated in
patients with acute lymphoblastic leukemia (ALL). Preclinical studies have demonstrated BCL-2 overexpression
and activity in human-derived pediatric cancer cell lines and several murine tumor models (Table 1) [1,6,9,10,12–29].
In particular, tumor models harboring the t(4;11) translocation are especially sensitive to venetoclax, most likely
due to the direct transcriptional upregulation of BCL-2 expression by the MLL–AF4 fusion protein [14]. The
Pediatric Preclinical Testing Program assessed venetoclax in 21 pediatric patient-derived xenograft (PDX) models
of ALL. Three of nine B-cell precursor ALL PDX models showed objective responses (two CR and one partial
response [PR]), and three of six mixed lineage leukemia (MLL) ALL PDX models showed strong responses to
venetoclax (two CR and one PR) [20]. In another study, venetoclax demonstrated potent in vitro and in vivo
activity in MLL-rearranged ALL xenografts, with significantly delayed progression in 11 of 19 (58%) xenografts.
MLL-rearranged and B-cell precursor subtypes had the longest median growth delay [21]. BCL-2 expression is
upregulated by TCF3–HLF, the product of the t(17;19)(q22;p13) translocation and hypodiploid ALL, both of
which are associated with extremely poor outcomes [16]. Specific sensitivity to venetoclax was achieved in both ex
vivo and in vivo TCF3–HLF-positive ALL samples [20,40,41] as well as hypodiploid ALL cell lines and PDXs [17].
Most patient-derived neuroblastoma cell lines are particularly sensitive to venetoclax treatment in vitro, most
likely due to BCL-2 expression and its sequestration of the prodeath protein BIM [27]. Studies in neuroblastoma
murine xenografts showed that single-agent venetoclax treatment led to long-term survival in 20% of mice. When
combined with cyclophosphamide, survival rates were substantially increased to 60% (Table 1) [1,6,9,10,12–29].
Phase I trial
Herein we describe the design of the venetoclax pediatric trial (M13–833), an open-label, global Phase I study
(EudraCT 2017–000439–14; NCT03236857) evaluating the safety, pharmacokinetics and preliminary efficacy
of venetoclax in pediatric and young adult patients with relapsed/refractory malignancies. This trial is the first
study of venetoclax in pediatric patients, and incorporates a novel study design. The study will be conducted in
accordance with the protocol, International Conference on Harmonization Good Clinical Practice guidelines and
applicable regulations and guidelines governing clinical study conduct and ethical principles that have their origin
in the Declaration of Helsinki. All patients must provide written informed consent (in addition to pediatric assent,
if required) approved by an independent ethics committee/institutional review board, prior to initiation of any
screening or study-specific procedures.
Objectives
The primary study objectives are to evaluate the safety, determine the DLT and RP2D and assess the pharmacoki-
netics of venetoclax monotherapy in pediatric patients. The secondary objectives are to determine the preliminary
efficacy of venetoclax monotherapy, and to evaluate the safety and preliminary efficacy of venetoclax in combina-
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Evaluate initial PK and safety
and establish recommended
dose for Part 2
Part 2
(cohort expansion)
n = 44–125
ALL
AML
NHL
Neuroblastoma
Other tumors¶
Venetoclax ramp-up
800-mg adult-equivalent target
dose (age/weight adjusted)§
Part 1
(dose determination)
n = 10†
Any relapsed/refractory tumor‡
Figure 2. Two-part study design.
†The first ten patients will be pediatric patients <18 years of age; a maximum of 20 patients may enroll.
‡Excluding brain tumors.
§Potential to de-escalate or escalate.
¶Must have evidence of BCL-2 expression and includes patients with TCF3-HLF ALL.
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; NHL: Non-Hodgkin lymphoma; PK:
Pharmacokinetic.
tion with chemotherapy appropriate to the diseases of patients enrolled. The exploratory objectives are to evaluate
pharmacodynamic and predictive biomarkers (including BCL-2 family expression), and to assess minimal residual
disease (MRD) in peripheral blood and bone marrow (particularly for patients with acute leukemias).
Study design
This trial will follow a two-part study design (Figure 2) consisting of dose determination (Part 1) and cohort
expansion (Part 2). Part 1 will enroll pediatric and young adult patients with any relapsed/refractory tumor type who
have no available curative options. During Part 2, four tumor cohorts will enroll patients with relapsed/refractory
ALL, AML, NHL or neuroblastoma. An exploratory fifth cohort will enroll patients with any tumor that has
evidence of BCL-2 expression and no available treatment options, or patients with TCF3–HLF ALL confirmed
during frontline induction.
Treatment
Two formulations of venetoclax will be available. Tablets for oral suspension, an age-appropriate formulation, will
be used in Part 1. In a relative bioavailability study in healthy participants, the bioavailability of the tablets for
oral suspension was found to be similar to that of the oral adult tablet when taken with a high-fat meal. Since the
pharmacokinetics of the two formulations are similar, in Part 2, patients will choose between the approved oral
tablet formulation, or tablets for oral suspension if they are unable to swallow tablets [7,8].
Oral venetoclax monotherapy will be administered once daily, continuously. The initial target dose in Part 1
will be an exposure-equivalent dose to the 800-mg venetoclax dose used in adults, that will be weight or age
adjusted [4]. Venetoclax is metabolized by CYP3A, which is not fully mature in humans until they reach the age
of 2 years. Therefore, this may affect hepatic elimination of venetoclax. In this trial, patients <2 years old will
be dosed primarily according to their age (Tables 2 & 3) [42]. Patients who are 2 years of age and older will be
dosed according to their weight (Tables 2 & 3). Ultimately, pharmacokinetic data from this study will be used to
assess the impact of age and weight on venetoclax pharmacokinetic parameters (i.e., apparent clearance and volume
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Table 2. Venetoclax dose ramp-up in patients with hematologic malignancies or lymphomas.
Dose groups 3-day ramp-up to 800-mg adult exposure-equivalent target dose of venetoclax
Day 1, mg Day 2, mg Day 3 and onward, mg
Age:
– Newborn to 1 month
– 1 to 3 months
– 3 to 6 months
– 6 months to 1 year
– 1 to 2 years
2.5
5
10
25
40
5
10
25
50
80
10
25
50
100
150
Weight:
– 10 to 20 kg
– 20 to 30 kg
– 30 to 45 kg
– ≥45 kg
50
80
120
200
120
170
250
400
250
350
500
800
Table 3. Venetoclax dose ramp-up in patients with solid tumors.
Dose groups 2-day ramp-up to 800-mg adult exposure-equivalent target dose of venetoclax
Day 1, mg Day 2 and onward, mg
Age:
– Newborn to 1 month
– 1 to 3 months
– 3 to 6 months
– 6 months to 1 year
– 1 to 2 years
5
10
25
50
80
10
25
50
100
150
Weight:
– 10 to 20 kg
– 20 to 30 kg
– 30 to 45 kg
– ≥45 kg
120
170
250
400
250
350
500
800
of distribution) to determine dosing instructions for pediatric patients. The pediatric target doses are currently
projected on the basis of matching safe and efficacious exposures achieved in adults at the 800-mg dose, and using
population pharmacokinetic modeling techniques to select doses; at least ten pediatric patients are required.
To mitigate TLS risk, venetoclax doses will ramp up to the target dose. Due to the increased risk of TLS in
patients with leukemia or lymphoma, these patients will ramp up over 3 days (adult exposure-equivalent doses of
200 mg day 1, 400 mg day 2 and 800 mg day 3), detailed in Figure 3A & Table 2. Patients with solid tumors will
ramp up over 2 days (adult exposure-equivalent doses of 400 mg day 1 and 800 mg day 2), detailed in Figure 3B
& Table 3. TLS has rarely been observed in pediatric patients with solid tumors [43]. All patients will receive TLS
prophylaxis measures, including hydration, a uric acid-reducing agent (allopurinol or rasburicase) and laboratory
monitoring as clinically indicated, but at a minimum of predose, 4, 8 and 24 h postdose until venetoclax target
dose is achieved (Figure 3A & B).
Evidence from preclinical and adult studies suggests venetoclax is most likely to be effective in combination
with chemotherapy; therefore, alongside establishing the safety of the single agent, patients will be permitted to
receive combination of venetoclax with chemotherapy after a venetoclax monotherapy window, as determined by
their diagnosis. During Part 1 and 2, patients may receive venetoclax in combination with chemotherapy following
documentation of response tomonotherapy at the first disease assessment (thismay include disease progression at the
first assessment or earlier if suspected and confirmed). For patients with leukemia, combination with chemotherapy
will be allowed commencing week 4 (day 22), and for patients with lymphoma and solid tumors, commencing week
8. Allowed chemotherapies were selected on the basis of available venetoclax + chemotherapy data from clinical
trials in adults (for AML and NHL patients), salvage regimens commonly used for relapsed pediatric tumors or
preclinical data, as summarized in Table 4. Patients who progress on venetoclax + chemotherapy will come off the
study.
Part 1 (dose determination)
In Part 1, a minimum of ten pediatric patients (<18 years of age) will be enrolled. On the basis of pharmacokinetic
parameter variability observed with the tablets for oral suspension, pharmacokinetic data from ten patients will
yield a two-sided 95% CI within 60 and 140% of the geometric mean parameter estimate with approximately 95%
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Day 1
Day 2
Day 3
Ongoing venetoclax
(9-month study duration)†
First assessment:
Week 4 (day 22) after initiation
for ALL and AML patients;
week 8 for NHL patients
Day 1
Day 2
Ongoing venetoclax
(9-month study duration)†
First assessment: Week 8
Hospitalization: On or before day 1
until 24 hours after the target dose is
reached
TLS monitoring and prophylaxis
• Oral/IV hydration per institution
   guidelines
• Uric acid-reducing agents prior to
   dosing
• Laboratory monitoring 0, 4, 8, and
   24 hours after each dose escalation
Combination with chemotherapy:
Permitted commencing week 4
(day 22) (ALL/AML) or week 8 (NHL)
of venetoclax monotherapy in patients
who tolerate venetoclax monotherapy
and obtain an objective response on
monotherapy. Patients must be
hospitalized for a minimum of 1 day
and receive TLS prophylaxis for
initial administration of venetoclax +
chemotherapy
Outpatient treatment: Permitted if
real-time monitoring of laboratory
assessments can be completed
TLS monitoring and prophylaxis
• Oral/IV hydration per institution
   guidelines
• Uric acid-reducing agents prior to
  dosing
• Laboratory monitoring 0, 4, 8, and
  24 hours after each dose escalation
Combination with chemotherapy:
Permitted commencing week 8 of
venetoclax monotherapy in patients
who tolerate venetoclax monotherapy
and obtain an objective response on
monotherapy. Patients must be
hospitalized for a minimum of 1 day
and receive TLS prophylaxis for
initial administration of venetoclax +
chemotherapy
Figure 3. Study overview. (A) Patients with ALL, AML and NHL. (B) Patients with neuroblastoma and other solid
tumors.
†Longer durations of therapy may be allowed.
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; IV: Intravenous; NHL: Non-Hodgkin lymphoma;
TLS: Tumor lysis syndrome.
probability. Additional patients (up to 20) may be enrolled to ensure sufficient enrollment across age, weight ranges
and tumor types, if the population of enrolled patients is not balanced and additional pharmacokinetic data are
required to evaluate other ages and weights. Of the population enrolled in Part 1, at least three patients must have
bone marrow involvement, and at least three patients must have disease without bone marrow involvement. The
collected pharmacokinetics data from ten pediatric patients will be evaluated using population pharmacokinetics
approaches, to enable understanding of age and weight effects on venetoclax pharmacokinetics. The initial target
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Table 4. Allowed chemotherapy regimens in combination with venetoclax for each tumor type.
Tumor type Allowed chemotherapy regimens
ALL Dexamethasone and/or vincristine and/or pegasparaginase
OR
Cytarabine and/or etoposide and/or pegasparaginase
ALL with Philadelphia chromosome or with an ABL class targetable fusion Tyrosine kinase inhibitor + above regimens for ALL
AML Low-dose cytarabine
OR
Hypomethylating agents: azacitidine/decitabine
NHL Rituximab and/or dexamethasone and/or vincristine
Neuroblastoma Cyclophosphamide and/or topotecan
Other tumors Cyclophosphamide and/or topotecan
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; NHL: Non-Hodgkin lymphoma.
dose will be an adult exposure-equivalent dose of 800 mg daily. Safe and efficacious exposures achieved in adults at
the 800-mg dose will be matched in pediatrics at the projected doses, as shown in Tables 2 & 3. Sufficient exposure
in children is identified as within twofold of the target exposure, to account for uncertainty in these projections and
observed pharmacokinetic variability in adults. The pediatric doses will be adjusted if needed, based on collected
pharmacokinetics data from Part 1 of the study, with the objective of achieving the mean and within twofold of
venetoclax-targeted efficacious area under the concentration–time curve steady state values.
For the purposes of dose-escalation decisions, DLTs will be assessed during the first 21 days of venetoclax
monotherapy. Separate DLT criteria will be utilized depending on tumor type (leukemias vs solid tumors), to
account for the prevalence of bone marrow involvement in patients with leukemia. As a result, hematologic
toxicities will not be used to define DLT in patients with ALL/AML. Safety data from the first three patients
enrolled in Part 1 will be evaluated after completion of the DLT assessment period and prior to enrollment of
additional patients.
To be evaluable for DLTs, patients must complete the first 21 days of venetoclax monotherapy with 80% drug
compliance, and be assessable for toxicities or experience a DLT within the 21-day DLT period. Patients who do
not complete the 21-day venetoclax monotherapy DLT period without a DLT will be considered unevaluable and
will be replaced, to obtain sufficient pharmacokinetic and safety data for analysis.
Dose de-escalation and escalation decisions will be made utilizing a Bayesian optimal interval (BOIN) design that
considers the cumulative number of patients who experience a DLT at the current venetoclax dose [44]. The target
toxicity rate utilized for the BOIN design is 33% and is applied to all tumor types. An initial cohort of three patients
will be enrolled and a safety evaluation performed prior to enrollment of additional patients. The cohort size for
subsequent patients is not similarly restricted. If 800-mg adult-equivalent venetoclax is not tolerated, a lower dose
of 400-mg adult-equivalent venetoclax will be evaluated as dose level-1. The MTD for venetoclax monotherapy
has not been reached in adult studies evaluating daily venetoclax monotherapy at doses up to 1200 mg [25,35].
The dose and schedule identified in Part 1 will be utilized in Part 2 of the study. The toxicity of venetoclax
combined with chemotherapy will be assessed separately. The DLT evaluation period is based on monotherapy
alone.
Part 2 (cohort expansion)
For Part 2, between 44 and 125 patients will be enrolled into four tumor cohorts: relapsed/refractory ALL, AML,
NHL and neuroblastoma. A fifth cohort that is exploratory in nature will enroll patients who have any tumor
that expresses BCL-2 and no available curative treatment options, or patients with TCF3–HLF ALL diagnosed
during frontline induction. As in Part 1, patients will initially be treated with venetoclax monotherapy until first
protocol-defined assessment, to fully evaluate the secondary objective of defining preliminary efficacy of venetoclax
monotherapy. After the first assessment, patients may receive venetoclax in combination with chemotherapy,
beginning week 4 (day 22) for patients with hematologic malignancies, and week 8 for patients with solid tumors,
unless a patient progresses before the first assessment at these times.
The four main tumor cohorts will utilize a Gehan two-stage design [45] to minimize unnecessary venetoclax
exposure to pediatric patients if there is no sign of activity. In the first stage, 11 patients will be enrolled in each of
the four tumor cohorts, and preliminary antitumor activity will be evaluated based on response criteria established
2122 Future Oncol. (2018) 14(21) future science group
Venetoclax in relapsed/refractory pediatric cancer Clinical Trial Protocol
Table 5. Key inclusion and exclusion criteria.
Inclusion criteria Exclusion criteria
– Adequate hepatic and renal function (aspartate aminotransferase and alanine
aminotransferase must be 3 × institutional upper limit of normal and total
bilirubin must be ≤1.5 × institutional upper limit of normal)
– Normal creatinine for age or calculated creatinine clearance
≥60 ml/min/1.73 m2, Lansky ≥50 (if ≤16 years of age), or Karnofsky ≥50 (if
16 years of age)
– In Part 1, patients must have relapsed/refractory cancer without available
curative treatment options
– Patients with solid tumors (with the exception of neuroblastoma) are required
to have adequate bone marrow function as defined by ANC ≥1000 cells/μl and
platelets 75,000 cells/μl (with transfusion independence defined as not receiving
platelet transfusion within 7 days prior to enrollment)
– In Part 2, patients must have relapsed/refractory ALL, AML, NHL or
neuroblastoma with histologically confirmed diagnosis
– For enrollment in the fifth cohort of Part 2, patients with other tumors must
have evidence of BCL-2 expression (determined locally, preferably utilizing
immunohistochemistry) or must have TCF3–HLF ALL confirmed prior to the end of
induction therapy
– Patients with primary brain tumors or disease metastatic to the brain, and patients
with leukemia having overt CNS disease (CNS 3 status); due to preclinical data
indicating that venetoclax is unlikely to penetrate a mature blood–brain barrier
– Patients who have received any of the following prior to the first dose of study
drug: biologic agent (i.e., antibodies) within 30 days; CAR T infusion or other cellular
therapy within 30 days; anticancer therapy including blinatumomab or
chemotherapy, radiation therapy, targeted small-molecule agents, investigational
agents within 14 days or 5 half-lives, whichever is shorter; steroid therapy for
antineoplastic intent within 5 days; ongoing hydroxyurea (hydroxyurea permitted
up to first dose)
– Patients who are 100 days post-transplant, or 100 days post-transplant with
active graft-versus-host disease, or requiring immunosuppression within 7 days prior
to first dose of study drug
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; ANC: Absolute neutrophil count; CAR: Chimeric antigen receptor; NHL: Non-Hodgkin lymphoma.
for each tumor type. The second stage will enroll 14 additional patients in an individual tumor cohort, provided
there is evidence of antitumor activity observed in any of the first 11 patients. The target response rate is 20%;
this is appropriate for each tumor type, as these patients would all be considered incurable. In addition, this target
response rate corresponds to the adult venetoclax monotherapy response rate observed in AML and NHL. The
fifth cohort will be exploratory. Statistical analyses will not be performed for the fifth cohort.
Key eligibility criteria
Eligible patients must be <25 years of age at enrollment; the inclusion of young adults in this trial is based on
the continued high unmet clinical need in this patient population that is generally underrepresented in clinical
trials [46]. Key eligibility criteria are summarized in Table 5.
Safety evaluations
Safety parameters will be evaluated throughout the study. Safety will be assessed by evaluating study drug exposure,
AEs according to the National Cancer Institute Common Terminology Criteria for AEs version 4.03 [47], serious
AEs, deaths and changes from baseline in laboratory tests. DLTs will be evaluated during the first 21 days of
monotherapy during Part 1.
Pharmacokinetic evaluations
Limited pharmacokinetic samples from peripheral blood will be collected during ramp up on days 1–3 of week
1 and on day 8 of week 2, when the target dose exposure is expected to reach steady state. Sparse samples
will also be collected during clinical visits on weeks 3, 4, 8, 12, 24 and every 12 weeks thereafter, and at final
visit. The sampling time points were selected based on the established pharmacokinetic profile of venetoclax in
adults [25,35,48,49], and to accommodate limitations in the number of blood samples that can be drawn from pediatric
patients (three-to-five samples/day on two occasions in Part 1, and one sample/visit on specified occasions). Plasma
concentrations of venetoclax (and if needed possible metabolite[s]), and pharmacokinetic parameter values will be
evaluated. Venetoclax doses will be adjusted if needed, based on pharmacokinetic data from Part 1. Overall analysis
of pharmacokinetic data along with safety assessments will inform dosing of venetoclax in Part 2.
Efficacy evaluations
Response will be assessed by the investigator based on standard established response criteria for each tumor type, as
summarized in Table 6 [50–52]. MRD in peripheral blood and/or bone marrow will be assessed by flow cytometry or
quantitative PCR as an exploratory objective when relevant. An objective response will be recorded for each patient
on venetoclax monotherapy, and for each patient on venetoclax combined with chemotherapy. Best response to
both monotherapy (including progressive disease) and combination therapy will be assessed. Patient survival data
will be collected until the end of the study.
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Table 6. Efficacy assessment criteria for each tumor type.
ALL/AML NHL Neuroblastoma Solid tumors
Criteria CR: hematologic recovery (ANC ≥500/μl; platelet count
≥75,000/μl)
CRi: CR except ANC 500/μl and/or platelets 75,000/μl
CRp: CR except platelets 75,000/μl (no transfusions or
support by exogenous growth factors)
PR: no peripheral blasts, or peripheral blood absolute blast
count decreased by ≥50% from baseline
SD/resistant disease: criteria for CR, CRi, CRp, PR or
progressive disease not met
Progressive disease: 50% increase in absolute peripheral or
bone marrow
Relapse: reappearance of blasts in the blood (unless
consistent with regenerating bone marrow) or bone marrow
(5% blasts) or in any extramedullary site after achieving CR
Lugano criteria [50] International neuroblastoma
response criteria [51]
RECIST v1.1 [52]
First assessment Week 4 (day 22 after initiation) Week 8
Frequency of
assessments
Monthly between week 4 and 12 and then every 12 weeks
thereafter, and at any other time point if clinically indicated,
including day 8
Week 24 and then every 12 weeks thereafter, and at any other time point if
clinically indicated, including week 4
ALL: Acute lymphoblastic leukemia; AML: Acute myeloid leukemia; ANC: Absolute neutrophil count; CR: Complete response; CRi: Complete response with incomplete marrow
recovery; CRp: CR without platelet recovery; NHL: Non-Hodgkin lymphoma; PR: Partial response; RECIST: Response Evaluation Criteria In Solid Tumors; SD: Stable disease.
Biomarker evaluations
Preclinical studies have contributed significantly to our understanding of BCL-2 biology, and have guided the
translational biomarker strategy for venetoclax [53]. These studies have shown that high BCL-2 expression is
commonly associated with greater in vitro sensitivity to single-agent venetoclax [1]. However, due to the dynamic
nature of other antiapoptotic proteins such as BCL-XL and MCL-1, which can sequester proapoptotic proteins
liberated from BCL-2, a broader expression profile may provide additional value for predicting responses to
venetoclax. Alternatively, high BCL-2 expression has been associated with known genetic lesions [1,11,14,20,40,54] that
offer potential surrogate markers of BCL-2 dependency; however, other mechanisms that contribute to venetoclax
sensitivity may not be captured, such as aberrantly active cell-signaling pathways or defects in mRNA-mediated
regulation. This dynamic interplay between multiple cellular systems may limit the utility of expression-based
markers as predictors of venetoclax sensitivity. One potential solution is to determine on which BCL-2 family
member a given cell population depends for survival, a method termed ‘BH3 profiling’ [55]. Thus, BH3 profiling
may provide an alternative, functional means of assessing tumor sensitivity to venetoclax. Similarly, proximity
ligation assays may be employed to extend the capabilities of traditional immunoassays to include detection of
direct protein–protein interactions, particularly BCL-2–BIM.
The overall objectives of the exploratory biomarker research in this study are to evaluate potential predictive
biomarkers of venetoclax preliminary efficacy, and to gain a better understanding of potential resistance mechanisms
to venetoclax. To enable these studies, peripheral blood, bone marrow and tumor tissue samples will be collected
according to tumor type at designated time points throughout the study to conduct exploratory biomarker analyses.
Biomarkers related to the pathway(s) targeted by the study drug (i.e., BCL-2 family expression levels) or biomarkers
related to the disease or to drug response/resistance may be evaluated for association with pharmacokinetics,
safety or efficacy. Samples may also be collected for functional and/or phenotypic analyses by BH3 profiling, for
hematologic malignancies, or proximity ligation assay for solid tumors. Results will be correlated with response
where applicable.
Statistical methods
The BOIN design [44] will be used to guide dose de-escalation/escalation decisions during Part 1; a Gehan two-stage
design [45] will be used to minimize unnecessary venetoclax exposure to pediatric patients during Part 2. Plasma
concentrations of venetoclax and metabolite(s) and pharmacokinetic parameters will be tabulated for each patient
and each dose level. Summary statistics will be provided for each dose level and each parameter. The following
efficacy analyses will be assessed: ORR (CR + CRi + CR without platelet recovery [CRp] + PR for hematologic
malignancies, CR + PR for NHL, neuroblastoma and solid tumors), CR rate, PR rate, MRD rate, overall survival
and progression-free survival. Statistical analysis will not be performed for the exploratory fifth cohort in Part 2
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due to the many different tumor types expected to be enrolled. All efficacy analyses will be performed using SAS R©
version 9.4 (SAS Institute Inc., NC, USA).
Conclusion
Pediatric patients with certain relapsed/refractory malignancies represent a population with extremely poor prog-
nosis. Advances in drug development in this high-risk population are hindered by low numbers of patients and
difficulties in enrolling patients onto traditional early phase studies that evaluate single-agent activity in these highly
refractory cancers. The venetoclax pediatric trial (M13–833) is a global study and the first to evaluate the safety,
pharmacokinetics and preliminary activity of venetoclax, a potent and highly specific BCL-2 inhibitor, in pediatric
patients. The current approach was driven by data (monotherapy and combination therapy) in adult patients
with malignancies that also occur in children (AML and NHL), and importantly, also by preclinical data across a
number of pediatric malignancies. Utilization of preclinical data ensures a mechanism-based approach for tumor
type selection and thus increased access to venetoclax for patients who may benefit. For example, an exploratory
cohort is included in Part 2 to allow enrollment of patients with tumor types that have insufficient data to warrant
a dedicated cohort.
International collaboration among academic clinicians and regulatory agencies (EuropeanMedicines Agency/US
FDA Oncologic Drugs Advisory Committee, Pediatric Subcommittee) is crucial, and this unique global study
incorporates input from the USA, EU, Australia and Canada on how best to design and conduct this clinical trial
for the greatest benefit to pediatric patients. This trial represents an example of national and international academic
clinicians and industry working in collaboration to streamline novel agents for therapy in pediatric patients [56].
To accelerate drug development efforts in children and young adults with cancer, this trial aims to overcome
issues in current pediatric clinical trials that potentially delay progress, in line with new guidelines developed by the
Innovative Therapies for Children withCancer (ITCC)Consortium. For example, this study utilizes a starting target
dose equivalent to that examined in adults, without performing dose escalation [4]. Venetoclax has been extensively
studied in adult patients with hematologic malignancies, thus providing a data set to inform development in the
pediatric setting. TheMTD of venetoclax monotherapy has not been reached in adult studies [25,35]. On the basis of
these data and pharmacokinetic modeling, a dose-determination design is used in Part 1 to validate that the 800-mg
adult-equivalent dose is appropriate, rather than a more traditional dose-escalation design that could require larger
numbers of patients, expose patients to subtherapeutic doses, and require longer time to execute. This also aligns
with the ITCC Consortium recommendation of a pediatric starting dose of 100% of the RP2D used for adults
to validate and/or confirm findings from adults [4]. This approach enables enrollment of a smaller number of
patients, with only ten pediatric patients initially required for Part 1 safety pharmacokinetics analysis, and facilitates
advancing to Part 2 of the study, which will focus on antitumor activity in specific tumor cohorts. Utilization of
expansion cohorts in Part 2 enables evaluation in specific tumor types selected on the basis of preclinical data and
data from clinical trials in adults, and will provide information about venetoclax in combination therapy more
rapidly than if done in separate, larger subsequent studies of each individual tumor type.
The current study does not have a lower age limit, due to the availability of a formulation suitable for infants.
Therefore, pharmacokinetic data could be available across a broader age range, including in infants and children
under 2 years of age, a group commonly underrepresented in many studies. Though the population for the current
study is limited to relapsed/refractory patients, there are certain subtypes of leukemias that occur and can relapse
in infancy. Additionally, the inclusion of young adults in this study is an approach to accelerate drug development
in this specific patient population that is underrepresented in clinical trials [4,46,56].
This study includes a monotherapy window to assess single-agent activity, and importantly, incorporates a
combination therapy portion to efficiently evaluate venetoclax in combination with chemotherapy, and facilitate
rapid transition to a larger-scale confirmatory study. The option to combine venetoclax with chemotherapy after
a defined period of venetoclax monotherapy balances the need to understand pediatric-specific pharmacology and
toxicology of a single agent while optimizing an individual patient’s chance of deriving clinical benefit, and should
help optimize accrual of patients whose disease may benefit from targeted inhibition of BCL-2 alone and/or in
combination therapy. Preliminary data from ongoing adult studies have shown that a combination approach can
lead to higher ORR and CR rates compared with venetoclax monotherapy [12,13,26,57]. It should be noted that
pretreatment with venetoclax alone may alter the tumor biologically to affect the efficacy of the venetoclax and
chemotherapy combination. However, defining the toxicity of the combination therapy within this trial facilitates
starting future combination studies.
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In addition, correlative analysis performed in this study will seek to identify whether genetic, immunohisto-
chemistry expression or protein–protein interactions provide better insight into critical biomarkers for venetoclax
in pediatric patients, and distinguish specific patient populations that will clinically benefit most from venetoclax
therapy.
This study maximizes efficiency in pediatric early phase trial design, by combining multiple elements in a single
study with the goal of efficiently advancing to subsequent larger-scale studies in a timely manner. The novelty of the
design, correlative analysis and the unique international and industry collaborations that are working to streamline
novel therapeutics in pediatric cancer aim to improve the overall risk:benefit ratio in children.
The results of the described clinical trial may lead to a novel therapeutic avenue for pediatric patients who have
limited treatment options. Recruitment of this trial began in October 2017.
Executive summary
• Novel study designs are required for pediatric patients with certain relapsed/refractory malignancies who have
poor prognosis and limited treatment options.
• The antiapoptotic BCL-2 protein is overexpressed in many hematologic malignancies and certain solid tumors,
and represents a promising therapeutic target for pediatric cancer patients.
Venetoclax
• Venetoclax is a highly selective, potent and orally bioavailable first-in-class BCL-2 inhibitor.
• Venetoclax has shown promising activity in adult studies across several hematologic malignancies, and studies in
pediatric patient-derived xenograft models and cell lines have demonstrated venetoclax activity in acute
lymphoblastic leukemia (ALL), acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL) and neuroblastoma.
Phase I trial
• The venetoclax pediatric trial (M13–833) is an open-label, global Phase I trial (EudraCT 2017–000439–14;
NCT03236857) and the first study of venetoclax in pediatric patients.
• The primary objectives of the study are to evaluate the safety, determine the dose-limiting toxicities and the
recommended Phase II dose and assess the pharmacokinetics of venetoclax monotherapy.
• The secondary objectives are to determine the preliminary efficacy of venetoclax monotherapy, and to evaluate
the safety and preliminary efficacy of venetoclax in combination with chemotherapy.
• A biomarker strategy is a key exploratory objective of this trial.
Study design & treatment
• In Part 1 (dose determination), patients with any relapsed/refractory tumor will receive oral venetoclax once
daily and ramp up to the adult venetoclax exposure-equivalent dose of 800 mg that is weight or age adjusted.
• Dose-limiting toxicities will be evaluated during the first 21 days of monotherapy.
• Part 2 (cohort expansion) will enroll with histologically confirmed relapsed/refractory ALL, AML, NHL or
neuroblastoma, and use the venetoclax dose and schedule identified in Part 1. A fifth exploratory cohort will
enroll patients with any tumor that expresses BCL-2, or patients with TCF3-HLF ALL diagnosed during frontline
induction.
• Patients may receive venetoclax in combination with chemotherapy following documentation of response to
monotherapy at the first disease assessment (or earlier if progressive disease).
Conclusion
• The venetoclax pediatric trial (M13–833) will combine multiple elements of study designs into one trial in an
international collaborative academic and industry effort to accelerate drug development in pediatric cancer
patients.
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